Sareum Holdings Plc (LON:SAR) has noted that its partner Sierra Oncology has been granted patents in the US and Europe that explicitly give greater protect for its anti-cancer Chk1 inhibitor candidate SRA737.
Tim Mitchell, Sareum’s chief executive, said: "SRA737 is a valuable asset to Sareum through its licence to Sierra Oncology. We are pleased to see that patents to protect it have been granted in these major territories."
Sierra Oncology holds exclusive and worldwide rights for the Chk1 inhibitor, SRA737. It licensed the programme from Sareum's co-investment partner, the CRT Pioneer Fund in September 2016.
No milestone payments are triggered by the additional patent protection.